CordenPharma is committing €80 million to expand sterile injectable manufacturing at its Caponago site near Milan, combining additional property with new isolator-based filling equipment, inspection, secondary packaging, and analytical capacity.
The multi-year programme includes €13 million already spent on an 11,000 sq m commercial building and 26,000 sq m of adjacent land. The acquisition was completed on 28 July and increases the Caponago footprint by more than 50%, giving the company room for a further generation of customer-specific sterile manufacturing lines.
CordenPharma says the newly acquired building can accommodate at least four aseptic fill-and-finish lines and four visual-inspection lines, alongside additional packaging capacity. Possible configurations also include large-scale lyophilisation, auto-injector assembly, and customer-owned equipment, allowing the company to shape the space around individual programmes rather than committing the entire building to one process.
Separately, two new isolator-based lines are already being added within an existing operational area at Caponago. One is a Bausch & Ströbel combination line for pre-filled syringes, vials, and cartridges aimed at clinical and smaller commercial batches, while the other is a higher-speed Syntegon line for pre-filled syringes and cartridges.
The Syntegon installation is specified for output above 500,000 units per day. The wider programme also expands automatic secondary packaging for syringes, vials, and ampoules and doubles analytical capacity, with completion of the two new isolator lines targeted for mid-2027 and 2028 respectively.
CordenPharma ultimately projects total Caponago capacity of up to 500 million injectable units annually. The site is intended to support products based on peptides, lipid nanoparticles, small molecules, biologics, oligonucleotides, and other complex modalities across therapeutic areas including oncology, obesity, diabetes, and inflammatory disease.
Dr Michael Quirmbach, president and chief executive of CordenPharma Group, said the investment would “enhance our end-to-end supply capabilities” as demand for injectable outsourcing increases.
The expansion reflects a manufacturing problem created by increasingly complex drug pipelines. Developers may need comparatively small clinical batches initially but require a credible route into much larger commercial volumes if a medicine succeeds, making repeated transfers between unrelated equipment and sites an additional source of technical and regulatory risk.
Flexible filling formats help reduce that discontinuity. Pre-filled syringes, cartridges, liquid vials, lyophilised products, and auto-injectors all impose different handling and packaging requirements, so a CDMO able to configure several line types can support a broader group of products without assuming that one container format will dominate future demand.
Aseptic production places particular pressure on facility and equipment design because exposed sterile product must be protected from contamination throughout filling and closure. Isolator technology creates a physical barrier between critical operations and the surrounding room, reducing direct personnel intervention around the filling zone while retaining tightly controlled transfer and decontamination procedures.
The isolator is only one part of the manufacturing system. Formulation, component preparation, clean utilities, inspection, analytical testing, secondary packaging, warehousing, and batch release all have to keep pace with the filling operation if additional machine speed is to become usable commercial capacity.
CordenPharma’s decision to double analytical capability and increase packaging and inspection alongside the filling lines is therefore as important as the headline output of the machines themselves. A line capable of filling hundreds of thousands of units a day simply moves the bottleneck downstream if those units then wait for inspection, analysis, or packaging.
The company’s previous Caponago investment programme has already expanded secondary packaging and development facilities, while the site supports injectable manufacturing alongside capabilities connected with complex drug modalities. That gives customers the option of placing several development and manufacturing steps within one CDMO network, although each product still requires its own technology transfer, validation, and regulatory control strategy.
The property acquisition also creates flexibility around future demand. Pharmaceutical plants are expensive to reconfigure once cleanrooms, utilities, material routes, and validated equipment are fixed, so securing adjacent space before every line has been specified can be cheaper than attempting to expand onto a constrained site later.
It also carries risk. Nameplate capacity has little value until buildings are converted, equipment is installed, utilities are qualified, processes are validated, and customer programmes occupy the lines. CordenPharma’s projected 500 million-unit figure is therefore a future capacity ambition tied to the full development programme rather than current annual output.
The next two years will determine how quickly that planned capacity becomes usable. The property transaction is complete, two isolator lines are moving through installation, and further space is available for later expansion. For Caponago, the engineering challenge has shifted from finding room to turning that room into qualified sterile production without allowing inspection, analysis, or packaging to become the next constraint.
